洁特生物(688026) - 2023 Q4 - 年度业绩(更正)

Financial Performance - Total operating revenue for 2023 was revised to RMB 463.10 million, a decrease of 24.06% compared to the previous year[3] - Operating profit was adjusted to RMB 39.44 million, reflecting a decline of 58.95% year-over-year[3] - Total profit was corrected to RMB 38.32 million, down 60.90% from the prior year[3] - Net profit attributable to shareholders of the parent company was revised to RMB 34.79 million, a decrease of 60.34% compared to last year[3] - Basic earnings per share were adjusted to RMB 0.25, representing a 60.32% decline year-over-year[3] - The weighted average return on net assets was revised to 3.03%, a decrease of 5.36 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 162.61 million, an increase of 1.29% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was adjusted to RMB 115.70 million, reflecting a 1.54% increase[3] Adjustments and Apologies - The adjustment in financial data was primarily due to the reversal of share-based payment expenses amounting to RMB 7.72 million related to the 2021 restricted stock incentive plan[7] - The company expressed apologies for any inconvenience caused to investors due to the adjustments made after thorough communication with the auditing firm[8]